<DOC>
	<DOCNO>NCT01621906</DOCNO>
	<brief_summary>The purpose study compare two different image method examine response brain metastasis WBRT . These two image method take picture brain use : 1 ) positron emission tomography ( PET ) scanner 2 ) Magnetic Resonance Imaging ( MRI ) scanner . A PET scanner resembles CT MR scanner.PET scan use radioactive substance also call radioactive marker `` see '' cancer cell . We plan use [ 18F ] FLT radioactive marker . FLT use image tumor growth . FLT PET scan new clinical procedure . It test stage development unlike FDG-PET use commonly use . Therefore , consider `` research '' study . This help u evaluate whether scan safe good use future evaluate tumor . The amount radiation body small . The radiation radiotracer drug go body hour . There radiation risk MRI scan . Additionally , also plan use MRI image brain . We expect [ 18F ] FLT PET well compare MRI give u information brain metastasis WBRT .</brief_summary>
	<brief_title>18F-FLT-PET Imaging Brain Patients With Metastatic Breast Cancer Brain Treated With Whole Brain Radiation Therapy With Without Sorafenib : Comparison With MR Imaging Brain</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Alovudine</mesh_term>
	<criteria>Histologicallyconfirmed ( confirmation do MSKCC ) metastatic adenocarcinoma breast Radiologic evidence new and/or progressive brain metastasis ( ( ≥10 mm long dimension ) MRI image Brain Planned WBRT base number ( ≥ 3 lesion ) and/or size ( ≥ 1 cm ) brain metastasis . Age ≥18 year ; male females Patients require additional clinically indicate stereotactic radiosurgery ( SRS ) addition WBRT also eligible . Life expectancy &gt; 12 week . Karnofsky Performance Status ( KPS ) ≥ 70 % . Creatinine ≤2.0 time upper limit normal . Women childbearing potential must negative serum pregnancy test perform within 7 day prior enrollment , must nonlactating must agree use adequate contraception prior enrollment duration study participation . No limit prior therapy last anticancer treatment ≥2 week initiation WBRT . Please note : washout period require trastuzumab , pertuzumab , patient develop new parenchymal brain metastasis agent . Leptomeningeal metastases Please note : leptomeningeal metastasis may allow limited cranial metastasis ( MRI spine complete , within 4 week enrollment , show leptomeningeal metastasis present ) metastasis present brain . Concurrent administration lapatinib tyrosine kinase inhibitor sorafenib Craniotomy major surgery , open biopsy , significant traumatic injury within 4 week randomization . Concurrent anticancer therapy ( chemotherapy , hormonal therapy , radiation therapy , surgery , immunotherapy , biologic therapy , tumor embolization ) sorafenib , protocolspecified wholebrain radiotherapy . Use investigational drug within 30 day 5 halflives , whichever longer , precede enrollment . Inability comply protocol /or willing available followup assessment . Any condition investigator 's opinion make patient unsuitable study participation . Patient incontinent urine stool ( would make unable tolerate lying still 60 minute ) . Claustrophobia Known allergic reaction GdDTPA Renal insufficiency recent ( &lt; 3 month old ) creatinine &gt; 2.0</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Breast</keyword>
	<keyword>brain metastasis</keyword>
	<keyword>18F-FLT-PET Imaging</keyword>
	<keyword>FLT ( 3'DEOXY-3'FLUOROTHYMIDINE )</keyword>
	<keyword>MR Imaging</keyword>
	<keyword>12-039</keyword>
</DOC>